Skip to content

Visix 2.3.9

by Televere Systems

Visix 2.3.9 is a Class II device made by Televere Systems, cleared under FDA 510(k) K082623 on 25 Feb 2009 and listed in FDA GUDID since 27 Sep 2016 (UDI-DI 00851800007030), active as of 22 Oct 2026.

Active United States. Also listed in GUDID (US).

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

510(k) K082623

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number00851800007030 UDI-DI Date27 Sep 2016ListedStatusListed GUDID: in commercial distribution
United StatesFDA 510(k)SESE from GUDID Substantially Equivalent · Traditional NumberK082623 Date25 Feb 2009DecidedStatusActive

Official records

Across registries

2 registries list this device

  • FDA 510(k) K082623 decided 25 Feb 2009 Active
  • FDA GUDID UDI-DI 00851800007030 listed 27 Sep 2016 Listed

Timeline

2 dated events

  1. Cleared FDA 510(k) K082623
  2. Listed FDA GUDID 00851800007030

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

GUDID

Trade name
Visix
Generic name
Radiological PACS-dedicated management software
Model / Ref / Catalog
2.3.9, Visix 2.3.9
Primary DI / UDI-DI
00851800007030
510(k) Number
FDA product code
LLZ
GMDN term
Radiological PACS-dedicated management software
Device class
Class II
Regulation number
892.2050
GUDID distribution status
In Commercial Distribution

Similar devices

Other devices filed under FDA product code LLZ (System, Image Processing, Radiological).

Other devices from Televere Systems

  • TigerView 8.6

    Class II
  • TigerView 8.1 Build 81

    Class II
  • Visix 7.7.15

    Class II
  • TigerView 8.3

    Class II

See all devices from Televere Systems →

Properties

  • Lot / batch number
Other properties (14, all answered No)